The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Male and Female subjects must be ≥18 and <90 years of age;
Able to understand and provide informed consent prior to study procedures
Must be in good health
Less than 18 years of age;
None
6
Treatment groupsSee each treatment group below.
Yale University
Lead sponsor
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Collaborator
National Institute on Aging (NIA)
Collaborator